WallStSmart

CryoCell International Inc (CCEL)vsTenet Healthcare Corporation (THC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Tenet Healthcare Corporation generates 68489% more annual revenue ($21.45B vs $31.28M). THC leads profitability with a 7.9% profit margin vs -8.5%. CCEL appears more attractively valued with a PEG of 1.34. THC earns a higher WallStSmart Score of 66/100 (B-).

CCEL

Hold

39

out of 100

Grade: F

Growth: 2.7Profit: 5.5Value: 7.0Quality: 5.5
Piotroski: 6/9Altman Z: -0.53

THC

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 5.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCELUndervalued (+34.8%)

Margin of Safety

+34.8%

Fair Value

$5.12

Current Price

$3.42

$1.70 discount

UndervaluedFair: $5.12Overvalued

Intrinsic value data unavailable for THC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEL2 strengths · Avg: 10.0/10
Return on EquityProfitability
129.2%10/10

Every $100 of equity generates 129 in profit

Debt/EquityHealth
-0.1310/10

Conservative balance sheet, low leverage

THC4 strengths · Avg: 9.5/10
P/E RatioValuation
10.7x10/10

Attractively priced relative to earnings

Return on EquityProfitability
35.4%10/10

Every $100 of equity generates 35 in profit

EPS GrowthGrowth
87.6%10/10

Earnings expanding 87.6% YoY

Free Cash FlowQuality
$1.46B8/10

Generating 1.5B in free cash flow

Areas to Watch

CCEL4 concerns · Avg: 2.3/10
Market CapQuality
$27.55M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-3.6%2/10

Revenue declined 3.6%

EPS GrowthGrowth
-80.5%2/10

Earnings declined 80.5%

Altman Z-ScoreHealth
-0.532/10

Distress zone — elevated risk

THC4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.8%4/10

2.8% revenue growth

Altman Z-ScoreHealth
1.734/10

Distress zone — elevated risk

Profit MarginProfitability
7.9%3/10

7.9% margin — thin

PEG RatioValuation
5.032/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEL

The strongest argument for CCEL centers on Return on Equity, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : THC

The strongest argument for THC centers on P/E Ratio, Return on Equity, EPS Growth.

Bear Case : CCEL

The primary concerns for CCEL are Market Cap, Revenue Growth, EPS Growth.

Bear Case : THC

The primary concerns for THC are Revenue Growth, Altman Z-Score, Profit Margin. Debt-to-equity of 2.74 is elevated, increasing financial risk.

Key Dynamics to Monitor

CCEL profiles as a turnaround stock while THC is a value play — different risk/reward profiles.

THC carries more volatility with a beta of 1.27 — expect wider price swings.

THC is growing revenue faster at 2.8% — sustainability is the question.

THC generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

THC scores higher overall (66/100 vs 39/100). CCEL offers better value entry with a 34.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CryoCell International Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.

Tenet Healthcare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Tenet Healthcare Corporation is a diversified health services company. The company is headquartered in Dallas, Texas.

Want to dig deeper into these stocks?